Biotech Firm To Pay $24M To Settle Clinical Trial Misstatement Claims
SAN FRANCISCO — A biotechnology company will pay $24 million to settle shareholder class claims that it and one of its senior executives failed to disclose negative clinical trial results for...To view the full article, register now.
Already a subscriber? Click here to view full article